Summary
Definition
History and exam
Key diagnostic factors
- paranoia
- odd thinking
- restricted range of emotions
- anger and irritability
- excessive emotionality and unstable mood states
- anxiety and tension
- impulsive behaviours
- grandiosity
- evidence of self harm (e.g., scars, burns)
Risk factors
- history of abuse
- family history of schizophrenia
- negative parenting interactions
- emotional/disruptive disorder in childhood
Diagnostic investigations
1st investigations to order
- clinical interview
Investigations to consider
- suicide risk screening questions
- Standardized Assessment of Personality-Abbreviated Scale (SAPAS)
- Millon Clinical Multiaxial Inventory-III (MCMI-III)
- Structured Clinical Interview for DSM-5-TR Alternative Model for Personality Disorders Version (SCID-5-AMPD)
- Structured Clinical Interview for DSM-5-TR Personality Disorders
- MRI/CT scan of brain
- urine drug screen
- The Primary Care Evaluation of Mental Disorders (PRIME-MD)
- Patient Health Questionnaire-9 (PHQ-9)
- Mood Disorder Questionnaire
- Generalised Anxiety Disorder-7 (GAD-7) and GAD-2
Treatment algorithm
at risk for harming self or others, or unable to attend to basic self-needs
cluster A (odd/eccentric): non-life-threatening
cluster B (dramatic): non-life-threatening
cluster C (anxious): non-life-threatening
multiple features of different personality disorders: non-life-threatening
Contributors
Authors
Michael J. Schrift, DO, MA
Professor
Department of Psychiatry and Behavioral Sciences
University of Washington
Seattle
WA
Disclosures
MJS declares he has no competing interests.
Acknowledgements
Dr Michael J. Schrift would like to gratefully acknowledge Dr Crystal T. Clark, and the late Dr Maria Devens, previous contributors to this topic. He would also like to acknowledge Dr Eric Gausche, who contributed the psychopharmacology sections for the initial version, and Dr Richard Stringham, who reviewed and approved information on the use of imaging and laboratory tests in the diagnosis section in the initial version. MD was an author of references cited in this topic. CTC, EG, and RS declare that they have no competing interests.
Peer reviewers
Anthony W. Bateman, FRCPsych
Consultant Psychiatrist and Visiting Professor
Halliwick Psychotherapy Unit
St Ann’s Hospital
London
UK
Disclosures
AWB declares that he has a bias towards the use of mentalization in the treatment of personality disorder.
Robin L. Kissell, MD
Director
Borderline Personality Disorder Initiative
Semel Institute
UCLA
Los Angeles
CA
Disclosures
RLK declares that she has no competing interests.
Justin Trevino, MD
Medical Director
Opioid Treatment Program
Dayton Veterans Affairs Medical Center
Dayton
OH
Disclosures
JT declares that he has no competing interests.
Dietmar Winkler, MD
Department of Psychiatry and Psychotherapy
Medical University of Vienna
Vienna
Austria
Disclosures
DW has received lecture fees from CSC Pharmaceuticals, GlaxoSmithKline, and Pfizer, and has served as a consultant for GlaxoSmithKline.
Differentials
- Mood disorders
- Psychotic disorders
- Anxiety disorders
More DifferentialsGuidelines
- Treatment guidelines for personality disorders
- Screening for suicide risk in adolescents, adults, and older adults in primary care
More GuidelinesPatient information
Personality disorders: what are they?
Personality disorders: what treatments work?
More Patient information- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer